Animal Health
Biotech
GMP
Intellectual Property
Legal
Management Skills
Medical Devices
Pharmaceutical
Support Staff

Sponsoring & Exhibiting

For sponsorship and exhibition opportunities at Management Forum events click here

Event Management

To find out about event management click here

Speaking Opportunities

Speaking opportunities are available on selected Management Forum events, please contact us for further information

Management Forum Brochure

Download our catalogue here

Medical Devices

Connectivity in Medical Technology

There are no dates confirmed for this course yet. Please contact us for further information.

Bespoke training

We can customise this course to meet the requirements of your organisation.

Learn more

Course overview

our media partner

We are at the start of an industrial revolution in medical devices. The possibilities for medical devices to wirelessly connect, analyse and disseminate information as well as for controlling the device remotely are being realised. For example, there are already pacemakers that can be remotely monitored and programmed and blood glucose meters which stream data to a smart phone and the Internet. There are a myriad of wirelessly connected devices in development such as smart phone control nerve stimulation devices, devices which monitor adherence to a prescribed therapeutic regimen and devices with medical mobile apps.

The consumer health sector has led the way, with small wearable technologies that, collect data on activity rates, vital signs and provide the user with information on distance covered, calories burned and other information they may want. The data can be displayed on a mobile phone app and on a PC via the Internet.

The smart phone is a great enabler of this revolution, providing a handy tool with advanced and secure communication to vast sections of the population. However, in the medical device context smart phones are fraught with problems. There are numerous platforms and several operating systems. These tend to evolve much more rapidly than medical devices do. Verifying a mobile app across all of the evolving platforms and operating systems, to the satisfaction of regulatory agencies, presents a significant challenge.

Furthermore, a number of systems require development to:

  • Monetize the benefits associated with a connected medical device
  • Handle the data which a connected medical device will generate
  • Help the healthcare professional make use of a connected medical device

This conference will start to explore this exciting new area of medical device technology.

Exhibitor

Programme insights

  • Impact of changing technologies on the healthcare market
  • Connectivity for pharmaceuticals and wider healthcare delivery
  • The evolving perspective of pharma on devices and connectivity
  • Connected health study: new app for ageing research
  • Point of care blood-glucose monitoring
  • I’m connected – does that make me smart?
  • Medical devices and patient engagement
  • 3 stories from the front line – scaling up in the UK
  • Powering Internet of medical things
  • Smart inhalers – improving patient compliance and reducing health costs
  • Tackling asthma control – expanding pre-cursor monitoring and revolutionising awareness
  • New FDA post market guidance for cybersecurity

Who should attend

Technical, marketing and commercial seniors:

  • Developers of connected medical devices
  • Marketeers promoting connected medical devices
  • Regulatory professionals
    Those with conventional medical devices who wish to introduce connectivity

Programme - Day one

9.30 Welcome and introduction

Dr Greg Berman, Independent Consultant, UK

Key note presentation

9.40 Impact of changing technologies on the healthcare market

  • Trends
  • Opportunities
  • Standards

Cecilia Bufton, Independent Business Adviser, UK

10.20 Connectivity for the pharmaceuticals and wider healthcare delivery

  • Use in clinical development
  • Improving compliance and clinical effectiveness
  • Delivering the human factors agenda for safety initiatives
  • Delivering wider health care benefits for patients and carers

Dr David Jefferys, Senior Vice President Global Regulatory, Government Relations and European Product Safety, Eisai Europe Ltd, UK

10.50 Discussion

11.00 Coffee

11.20 The evolving perspective of pharma on devices and connectivity

  • What is the pharma perspective?
  • How do we currently gather data ?
  • The patient perspective
  • Consumer electronics and pharma
  • Data, privacy, security and anonymity
  • The connected health jigsaw
  • Machine learning and looking for patterns
  • The Internet of things and health
  • Conclusions

Simon Wilson, Device Centre of Excellence, Pfizer, UK

10.50 Discussion

11.50 What´s in it for me? – The value of new technology

  • The evolution of drug delivery devices
  • The patient and his impact of driving innovation in healthcare
  • Success stories in implementing new technology in the marketplace

Markus Bauss, Managing Director, SHL Connect, Sweden

12.30 Discussion

12.45 Lunch

14.00 Connected health study: new app for ageing research

Marie McCarthy, Director of Product Innovation at ICON, Ireland

14.40 Point of care blood-glucose monitoring

  • Cobas Poc IT
  • Accu-Chek Inform II system

Representative from Roche Diagnostics

15.20 Discussion

15.30 Coffee

15.50 I’m connected – does that make me smart?

  • Connected devices
    • What makes a device smart?
    • What are the benefits of connected devices?
  • The convergence of technologies
    • What is driving down cost
    • Is the cost of connectivity low enough yet?
    • What is the cost threshold that might tempt payers to pay and investors to invest?
  • An example of a low cost connected medical device in development
  • An example of one way connectivity – is it smart enough?

Phil Seeney, Managing Consultant in the Technology and Innovation Practice, PA Consulting Group, UK

16.30 Medical devices and patient engagement

  • What is patient engagement and how does it relate to device connectivity
  • Drivers for patient engagement – device vendors, pharma, healthcare providers and patient
  • Various patient engagement models
  • The 3rd Pillar Clinical “Orchestrator” model : Improved patient outcomes from a marketing budget

Diarmuid Quinn, Director, 3rd Pillar Clinical, Ireland

17.10 Discussion

17.15 End of day one

17.15 – 18.15 Networking drinks reception for speakers and delegates

Programme - Day two

9.15 Review of day one

Dr Greg Berman, Independent Consultant, UK

9.30 Three Stories from the front Line – scaling up in the UK

  • Connected users
  • Yes, the NHS can adopt smartphone diagnostics
  • Working your way through college – creating AI

Francis White, VP Sales & Business Development, NHS Innovation Fellow, AliveCor Ltd, UK

10.10 Unconventional sensing for an unconventional world: connected technology to reveal how patients use new products

  • Using sensors and connectivity to achieve better patient adherence
  • When formative studies aren’t good enough
  • How to translate data driven insights into product development success

Jeremey Kooyman, Medical and Drug Delivery Device Design Engineer, The Cambridge Design Partnership, UK

10.50 Discussion

11.00 Coffee

11.30 End-to-end connected health solutions including medical devices and software

Thomas J Olesen, Independent Consultant

12.10 Case Study: 3M Intelligent Control Inhaler

Sam Van Alstyne, New Products Marketing Manager, 3M Drug Delivery

12.50 Discussion

13.00 Lunch

14.10 Smart inhalers – improving patient compliance and reducing healthcare costs

  • Global health data confirms that poor patient adherence to long-term therapies, such as asthma and COPD, contribute significantly to rising healthcare cost
  • Smart Inhalers are emerging which enable more effective monitory of patient compliance and adherence, including remotely
  • Clinical studies using smart devices have demonstrated improvements and translate directly to a reduction in healthcare cost
  • Smart Inhalers face numerous challenges, from a wide range of stakeholder, for successful adoption on a global scale

Dana Shears, Sales Director, The Americas, Presspart, USA

14.50 Tackling asthma control – expanding pre-cursor monitoring and revolutionising awareness

  • Self-awareness is subjective and poor self-awareness negatively impacts the action window for many
  • Pre-cursors based on advanced stages are easier to follow but less effective
  • Wearable technology takes the guess work out of self-awareness, identifying conditions without bias
  • Real time monitoring identifies difficult pre-cursors changing what proactive really is

Jarad Dwarika, Co Founder A.D.A.M.M. – Intelligent Asthma Management™, Health Care Originals Inc., USA

15.30 A Manufacturer’s perspective on the new FDA post market guidance for cybersecurity

  • What does the FDA guidance say
  • What is the background of this guidance?
  • What are its hidden assumptions?
  • What issues may show up in practice

Jim Jacobson, Chief Product and Solution Security Officer, Siemens Healthineers, USA

16.10 Discussion

16.20 Chairman’s concluding remarks

16.30 End of conference and tea

You may also be interested in...

EC Medical Devices Vigilance System and Post Marketing Surveillance

The Medical Device Summer School - From Concept to CE Marking

An Essential Overview of the Medical Device Industry

Wearable Drug Delivery

Previous customers include...

  • 3M Healthcare Ltd
  • Advanex Europe Ltd
  • Astellas Pharma Europe BV
  • Bespak Europe Ltd
  • Chiesi Farmaceutici SPA
  • GSK
  • Haselmeier AG
  • Imtool Sarl
  • Lastow Consulting
  • Medela AG
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Medicom Innovation Partner
  • Neuroderm LTD.
  • Noble International
  • Nokia
  • Nordic Semiconductor
  • Novo Nordisk A/S
  • Orthofix Srl
  • Owen Mumford Ltd
  • PA Consulting
  • PDD Group Ltd
  • Presspart Manufacturing Ltd
  • Reckitt Benckiser Health Care (UK) Ltd
  • S3 Group
  • Schreiner Group GmbH & Co KG
  • Sensium Healthcare Ltd
  • SHL Group
  • Smith & Nephew
  • Weidmann Medical Technology AG
  • Ypsomed AG